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A B S T R A C T
Background: Central adjudication of stroke type is commonly implemented in large multicentre clinical trials.
We investigated the effect of central adjudication of diagnosis of stroke type at trial entry in the Efficacy of Nitric
Oxide in Stroke (ENOS) trial.
Methods: ENOS recruited patients with acute ischaemic or haemorrhagic stroke, and diagnostic adjudication was
carried out using cranial scans. For this study, diagnoses made by local site clinicians were compared with those
by central, masked adjudicators using kappa statistics. The trial primary analysis and subgroup analysis by stroke
type were re-analysed using stroke diagnosis made by local clinicians, and simulations were used to assess the
impact of increased non-differential misclassification and subgroup effects.
Results: Agreement on stroke type (Ischaemic, Intracerebral Haemorrhage, Unknown stroke type, No-stroke) was
high (κ=0.92). Adjudication of stroke type had no impact on the primary outcome or subgroup analysis by
stroke type. With misclassification increased to 10 times the level observed in ENOS and a simulated subgroup
effect present, adjudication would have affected trial conclusions.
Conclusions: Stroke type at trial entry was diagnosed accurately by local clinicians in ENOS. Adjudication of
stroke type by central adjudicators had no measurable effect on trial conclusions. Diagnostic adjudication may
be important if diagnosis is complex and a treatment-diagnosis interaction is expected.
1. Introduction
Clinical trials in acute stroke often recruit many thousands of par-
ticipants making them complex, lengthy, and expensive. In many stroke
trials, key endpoints, adverse events, or diagnoses qualifying for trial
entry are adjudicated by independent experts. Independent, central
adjudication may be conducted by one individual or a panel of experts,
who may work independently or convene as a committee, with agreed
procedures for assigning definitive values, usually blinded to treatment
allocation whenever possible [1]. The adjudication procedure is be-
lieved to protect against bias resulting from differential misclassifica-
tion [2,3], and to improve precision of treatment estimates by reducing
‘noise’ from random errors. This is especially important in trials where
events are rare, in which a small degree of misclassification can have a
large impact on study findings [2,3] or where the event is subjective
such as some clinical diagnoses. Adjudication also introduces a level of
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quality control to detect poorly trained or performing investigators.
Central adjudication is commonly included in cardiovascular studies
[4,5], with conflicting evidence as to the value of adjudication of
endpoints [6–13] compared with simply using endpoints assigned by
local clinicians or investigators at participating research sites. There is
little research evidence regarding the importance of diagnostic ad-
judication, where diagnosis is not used as an endpoint, but is used to
diagnose patients at trial entry. Diagnoses made at trial entry can be
used to define eligibility, as a stratification or minimisation factor, as a
covariate in a regression model, or to specify categories in a subgroup
analysis.
Stroke is a clinical diagnosis that can be further subclassified based
on the results of further investigations, including brain and vessel
imaging and cardiac examinations. Given the complex nature of stroke
subtypes [14], stroke diagnoses are commonly adjudicated by in-
dependent experts in clinical trials. Ninomiya et al. [11] found that
adjudication of stroke type and cause of death as study endpoints had
no substantive impact on treatment effect estimates in their trial.
However, stroke diagnosis was an endpoint, rather than a criterion for
inclusion. While adjudication of endpoints has the greatest potential to
influence trial results and therefore has received greatest attention as to
its value, misclassification of entry criteria might also introduce bias,
affect the precision of effect estimates or reduce statistical power [15].
However, we are not aware of any such investigation of the value of
central adjudication of the diagnosis qualifying for trial inclusion.
The aim of this study was to investigate the value of central ad-
judication of stroke type at trial entry in a secondary analysis of a large
acute stroke trial. The three objectives were to [1]: compare stroke
diagnoses made by local clinicians and central masked adjudicators [2];
assess the impact of adjudication on the primary analysis and the
subgroup analysis by stroke type [3]; using simulation, explore the ef-
fects of increasing levels of misclassification of diagnosis and introdu-
cing a subgroup effect by stroke type on analyses.
2. Materials and methods
2.1. Efficacy of Nitric Oxide in stroke (ENOS) trial
The Efficacy of Nitric Oxide in Stroke (ENOS) trial examined the
safety and efficacy of glyceryl trinitrate (GTN) versus no GTN in pa-
tients with acute ischaemic or haemorrhagic stroke. Independent expert
assessors, referred to in this paper as adjudicators, who were masked to
treatment allocation, centrally assessed CT and MRI scans to inform
diagnosis of stroke type. The primary outcome was functional outcome
after stroke, measured using the modified Rankin Scale (mRS) at day 90
by outcome assessors who were masked to treatment allocation. The
trial recruited 4011 patients from 173 sites, across 23 countries on five
continents. The primary outcome was analysed using ordinal logistic
regression, and the adjusted common odds ratio (OR) for worse out-
come with GTN versus no GTN was 1·01 (95% CI 0·91 to 1·13;
p=0·83). The protocol, statistical analysis plan, and main results for
ENOS have been described in detail elsewhere [16–18].
2.2. Diagnosis of stroke type
After enrolment into the ENOS trial, all participants had a CT (or
MRI) scan at baseline or within seven days (referred to as baseline
scan), and if possible again after seven days (referred to as follow-up
scan) to assess evolution of the stroke lesion. Each scan was analysed by
local clinicians, who then used information from the baseline scan,
follow-up scan if available, input from the local radiology team, and
clinical history and assessment of the participant between admission
and discharge, in order to assign a clinical diagnosis for each partici-
pant (referred to as Local clinician diagnosis). The following diagnoses
were made: Ischaemic stroke, intracerebral haemorrhage, unknown
stroke and no stroke. All scans were then sent electronically to the
central trial team.
A team of independent, central adjudicators, masked to treatment
allocation and Local clinician diagnosis, assessed all brain scans. They
recorded their assessment using a specially designed questionnaire that
captured information on the presence of stroke, haemorrhage, occluded
arteries, Alberta stroke program early CT score [19], mass effect, white
matter disease, atrophy, and other visible lesions. This information was
used to determine an adjudicator diagnosis of stroke type for both
baseline and follow-up scans. A final diagnosis of stroke type for each
participant (referred to as Central adjudication diagnosis) was assigned
using an algorithm that assessed whether diagnoses from local clin-
icians and adjudicators sufficiently agreed, otherwise stroke diagnosis
was allocated on a case-by-case basis.
Central adjudication diagnosis was assigned using all available in-
formation from both local clinicians and adjudicators, and was thus
considered in this study as the ‘gold standard’. Local clinician diagnosis
represents the diagnosis of stroke type in ENOS if no central ad-
judication had taken place. In the ENOS analyses, stroke type at trial
entry was included in between-group comparisons as a baseline cov-
ariate, and as a subgroup variable to investigate any differential effects
of the interventions according to stroke type. The main ENOS analyses
used Central adjudication diagnosis of stroke. The analyses presented
here compared the main ENOS analyses with analyses conducted using
Local clinician diagnosis of stroke, thus allowing an investigation into
the value of adjudication of a baseline variable in ENOS.
2.3. Simulated misclassification of stroke type and simulated subgroup
effect
Statistical simulations were created to [1]: increase the extent of
misclassification of Local clinician diagnosis of stroke compared with
the gold standard Central adjudication diagnosis [2]; introduce an in-
teraction (subgroup effect) between ENOS treatment arm and stroke
type. These simulations enabled us to investigate the effects of mis-
classification on the ENOS primary analysis and on subgroup analysis,
for both the subgroup effect observed in ENOS and for a subgroup effect
introduced by simulation. The magnitude of the treatment-stroke type
interaction was increased in simulation as there was no statistical evi-
dence of a subgroup effect in the observed ENOS dataset.
In simulated datasets, the misclassification of Local clinician diag-
nosis observed in ENOS was increased by factors of 3, 5, 10, 15 and 20
(referred to as SX3, SX5, SX10, SX15 and SX20 respectively). We also
introduced a subgroup effect by reducing mRS score by 1 point for 10%
of participants with an Ischaemic stroke, and increasing mRS score by 1
point for 30% of participants with an Intracerebral Haemorrhage, with
mRS scores for all participants constrained to be in the normal range
0–6. All participants with an altered mRS score were in the GTN arm of
the trial. For more detailed simulation methods, please consult
Supplementary File S1.
2.4. Statistical methods
Categorical variables were described using N (%). Observed agree-
ment between Local clinician and Central adjudication diagnoses was
quantified using unweighted kappa statistics.
Using observed ENOS data, the effect of GTN treatment on mRS
score was estimated as in the ENOS trial main report, using ordinal
logistic regression models, adjusted for stratification and minimisation
variables. Models including Local clinician and Central adjudication
diagnosis of stroke type as a covariate were fitted separately and the
estimated effects of GTN treatment from the two models were com-
pared using a test of homogeneity. Similarly, subgroup effects were
estimated by fitting an interaction term between GTN treatment and
stroke type according to either Local clinician or Central adjudication
diagnosis.
The primary trial analysis was then repeated using each simulated
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level of Local clinician diagnosis misclassification (SX3 to SX20). The
subgroup analysis was also repeated for each simulated level of Local
clinician diagnosis misclassification for both the subgroup effect ob-
served in the ENOS dataset, and for the increased subgroup effect cre-
ated using simulation. Regression model coefficients and standard er-
rors are presented on the log scale for ease of comparison.
3. Results
Of 4011 participants randomised, 3857 (96%) and 1025 (26%) had
baseline and follow up scans respectively that were assessed by ad-
judicators. A total of 35 participants had a missing Local clinician di-
agnosis, and all participants had a Central adjudication diagnosis as-
signed after the combined information from the hospital and central
adjudicators was reviewed (Fig. 1).
The proportion of participants with each stroke type was similar for
those that did or did not have a follow-up scan, indicating no evidence
of bias in the selection of participants for a follow up scan and therefore
having more information with which to assign a diagnosis (see
Supplementary File, S2).
Agreement was high in ENOS, with local clinicians and central ad-
judicators agreeing on 79% of diagnoses at baseline. There was ex-
cellent agreement between Local clinician and Central adjudication
diagnoses (crude agreement 98%, unweighted kappa, κ=0.92) for the
3976 (99%) participants who could be included in this analysis
(Table 1).
Misclassification of Local clinician diagnosis resulted in kappa sta-
tistics for agreement between Central adjudication and Local clinician
diagnoses of 0.78, 0.67, 0.46, 0.32 and 0.21 for SX3-SX20 respectively.
As expected due to strong agreement between Central adjudication and
Local clinician diagnoses of stroke type, it made little difference which
one was used as a covariate in the primary analysis of observed ENOS
data (p-value for homogeneity p= 0.95, see Supplementary File, S3).
Similarly, coefficients and standard errors for the interaction between
GTN and stroke type were very similar regardless of whether Local
clinician or Central adjudication diagnosis of stroke type was used (data
not shown).
Increased levels of non-differential misclassification of stroke diag-
nosis introduced by simulation made no material difference to the es-
timated treatment effect of GTN or the precision of the estimate
(Table 2). Table 3 shows the effect of GTN separately for each stroke
type using the magnitude of subgroup effect observed in the ENOS data,
and where non-differential misclassification of stroke type is increased
by simulation. The number of participants diagnosed with ischaemic
stroke decreased, whilst each of the other types of stroke increased,
respectively, with increasing misclassification. The effects of mis-
classification on stroke-specific estimates of GTN treatment were not
wholly consistent, although increasing misclassification tended to give
treatment effects closer to zero and standard errors that increased or
decreased inversely with stroke-specific sample size accordingly.
Fig. 1. Flow diagram showing diagnosis of stroke type in ENOS.
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Simulation of a subgroup effect, whereby GTN was beneficial among
participants with an ischaemic stroke, and harmful among participants
with a haemorrhagic stroke, attenuated the treatment effects even
further (Table 4). After stroke type was increasingly misclassified using
simulation, statistical evidence of a subgroup effect was reduced and
the effects of subgroup sample size on precision were as expected
(Tables 4 and 5).
4. Discussion
Misclassification of stroke type by local trial site clinicians was low,
with excellent agreement found between the Central adjudication and
Local clinician diagnosis. Due to the level of agreement, there was little
impact of adjudication of stroke type at trial entry on the primary
analysis or subgroup analysis of ENOS. Increased levels of non-differ-
ential misclassification produced little change in the primary outcome.
After simulating a strong subgroup effect by stroke type, increased
misclassification resulted in reduction of the subgroup effect, sug-
gesting that in this situation adjudication may be important to ensure
robust results.
In ENOS, due to blinding, differential misclassification of stroke
type was unlikely, which was why we introduced non-differential
misclassification using simulation. Even with non-differential mis-
classification increased by 20 times the observed level, there was little
effect on both the primary and subgroup analyses. Only when a sub-
stantial subgroup effect (p < 0.01) and marked misclassification of
stroke diagnosis by local investigators were simulated would ad-
judication have resulted in differing conclusions. These extreme, and
thus arguably unlikely, conditions before central adjudication is seen to
add value are likely due to the fact that in our analyses, diagnosis of
stroke type is a baseline variable rather than a study endpoint. However
a recent Cochrane review [20] that assessed endpoint adjudication of
subjective binary events across a range of clinical areas, including 47
RCTs, also found that adjudication did not affect the treatment effect
estimates (Ratio of Odds Ratios: 1.00, 95% C.I: [0.97 to 1.04]). The
review suggested that adjudication ‘may be most important when onsite
assessors are not blinded and the risk of misclassification is high’.
It is worth noting that in ENOS, diagnostic adjudication was used for
purposes in addition to informing the diagnosis. The adjudication
process provided a large amount of extra information which hospital
scan results would not have recorded. This information can be used to
carry out imaging-based subgroup analyses or help to improve any
subsequent sub-studies. Furthermore, the central adjudication process
meant that each scan had been rated using a central, standard ap-
proach, enabling data to be pooled with other trials that have used a
similar method. Therefore, the ENOS data can be utilised further,
alongside existing data, to provide a larger sample size to test the
independent prognostic value and potential treatment implications of
the scan signs raised in various studies, as well as assisting in con-
firming or refuting ideas about not treating certain types of infarct or
effects on infarct swelling.
The diagnostic adjudication process in ENOS resulted in increased
complexity, and monetary and time costs. These included payments to
adjudicators, resources associated with handling adjudicator data (data
entry, database programming, and statistical analysis), the time taken
by the trial team to determine the trial diagnosis, and data queries.
Although this is the first study we are aware of to investigate diagnostic
adjudication in stroke trials, where diagnosis is not used as an endpoint,
previous studies which have looked at adjudication of endpoints have
found similar conclusions. Slight benefits of improving accuracy and
reducing misclassification were outweighed by the cost and complica-
tions introduced by an adjudication committee [2,11]. However, there
may be some unmeasurable benefits of an adjudication process, and
adjudication could have indirectly strengthened local assessment due to
a policing effect. This effect could have resulted in improved site per-
formance as investigators would have been aware that diagnoses would
have been checked centrally, and thus perform more carefully.
One strength of this study is that we used a large, well conducted,
randomised trial to provide data from over 4000 participants for ana-
lysis. Furthermore, the data completeness was extremely high, mini-
mising the risk of bias due to partially completed data. The simulation
undertaken in this study allowed an investigation into the robustness of
observed results to more extreme data scenarios. This was important to
understand how adjudication of diagnosis at trial entry could affect a
similar trial where agreement was not as good as observed in ENOS.
This approach, using a combination of observed and simulated data,
can be readily applied to secondary analyses of other trials, notably on
outcome variables as well as baseline variables, in order to inform fu-
ture studies.
A limitation of this study is that the potential for adjudication to
have an important effect is likely to be less for a baseline variable, as
seen in ENOS, rather than a primary outcome as in Ninomiya et al. [11].
Therefore, we also looked into the impact of adjudication on subgroup
analyses involving stroke type, to allow a thorough investigation into
the value of central adjudication of a baseline variable had on ENOS.
Furthermore, the treatment estimates for GTN for both ischaemic and
haemorrhagic stroke were similar, so increased misclassification in this
situation had limited impact, although this may not be the case in other
studies where there is a treatment-diagnosis interaction. Simulation
allowed us to explore this setting, but a further investigation using data
from another large trial would be beneficial to reinforce our findings.
Table 1
Agreement between Local clinician and Central adjudication diagnosis.
Crude agreement= 3884/3976=98%.
Unweighted kappa= 0.92.
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5. Conclusions
This study found that clinicians at ENOS trial sites largely were
correct in their diagnosis of stroke and adjudication did not impact on
the trial results. Adjudication of stroke type at trial entry would have
altered conclusions had there been strong evidence of a subgroup effect
by stroke type, and where misclassification was at least ten times that
observed in ENOS. In pilot or feasibility studies, misclassification could
be estimated in order to inform whether adjudication would be useful
in that particular trial. Researchers should consider the value ad-
judication could bring to their study before its implementation in a
clinical trial to avoid wasted time and unneeded expenditure.
List of abbreviations
ENOS – Efficacy of Nitric Oxide in Stroke.
GTN – Glyceryl trinitrate.
Ethics approval and consent to participate
Ethical approval was not required for this research due to it being a
secondary analysis of the ENOS trial where ethical approval was at-
tained. Written informed consent for the ENOS trial was obtained from
each patient, or, in the case when the patient did not have capacity,
from a relative or independent physician.
Availability of data and materials
The datasets used and/or analysed during the current study are
available from the corresponding author on reasonable request.
Conflicts of interest
The authors declare that they have no competing interests.
Role of the funding source
PJG is funded by a National Institute for Health Research Research
Methods Fellowship (RMFI-2014-05-13). PMB is Stroke Association
Professor of Stroke Medicine, and is a NIHR Senior Investigator. This
paper presents independent research funded by the NIHR through
PMB's Senior Investigator award. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the
Department of Health. The ENOS trial was primarily funded by UK
Medical Research Council. The funding sources had no involvement in
Table 2
Effect of increased misclassification of stroke type at trial entry on ENOS pri-
mary analysis.
Source of diagnosis of stroke type
at trial entry
Results from regression model comparing effect
of GTN versus no GTN
Log OR SE log OR
Central adjudication −0.02473 0.05565
SX3 −0.02446 0.05563
SX5 −0.02426 0.05563
SX10 −0.02426 0.05561
SX15 −0.02411 0.05561
SX20 −0.02415 0.05561
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics
showing the agreement between each diagnosis and Central adjudication di-
agnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for SX3-SX20 respectively.
Table 3
Effect of misclassification of stroke type at trial entry on subgroup analysis:
based on subgroup effect observed in ENOS data.
Stroke Type Source of diagnosis of
stroke type at trial
entry
N Subgroup-specific estimated effect
of GTN versus no GTN
Log OR SE log OR
Ischaemic Central adjudication 3338 −0.03048 0.06085
SX3 3096 −0.03114 0.06003
SX5 2935 −0.02953 0.06491
SX10 2531 −0.02503 0.06987
SX15 2129 −0.03130 0.07618
SX20 1725 −0.03043 0.08476
Haemorrhagic Central adjudication 623 0.02699 0.14110
SX3 657 0.02761 0.13717
SX5 682 0.01898 0.13474
SX10 739 0.01443 0.12943
SX15 798 −0.00496 0.12456
SX20 855 0.00832 0.12027
Unknown Central adjudication 1 –
SX3 196 0.00091 0.25320
SX5 325 −0.01070 0.19592
SX10 652 −0.03348 0.13830
SX15 975 −0.00867 0.11286
SX20 1302 −0.02353 0.09743
No-stroke Central adjudication 38 0.18475 0.65491
SX3 51 0.16043 0.54100
SX5 58 0.05159 0.48825
SX10 78 −0.00907 0.40673
SX15 98 −0.00359 0.36080
SX20 118 −0.00448 0.32877
Simulations produced datasets containing 4000 observations.
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics
showing the agreement between each diagnosis and Central adjudication di-
agnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for SX3-SX20 respectively.
Table 4
Effect of misclassification of stroke type on subgroup analysis: based on simu-
lated subgroup effect.
Stroke Type Source of diagnosis of
stroke type at trial
entry
N Subgroup-specific estimated effect
of GTN versus no GTN
Log OR SE log OR
Ischaemic Central adjudication 3338 −0.14122 0.06085
SX3 3096 −0.13885 0.06320
SX5 2935 −0.13576 0.06493
SX10 2531 −0.12591 0.06988
SX15 2129 −0.11477 0.07624
SX20 1725 −0.11388 0.08478
Haemorrhagic Central adjudication 623 0.29183 0.14156
SX3 657 0.25154 0.13760
SX5 682 0.22485 0.13522
SX10 739 0.17519 0.12990
SX15 798 0.11796 0.12482
SX20 855 0.08150 0.12015
Unknown Central adjudication 1 –
SX3 196 −0.09800 0.25358
SX5 325 −0.12723 0.19472
SX10 652 −0.15382 0.13795
SX15 975 −0.13565 0.11250
SX20 1302 −0.12854 0.09744
No-stroke Central adjudication 38 0.25680 0.68781
SX3 51 0.14555 0.53944
SX5 58 0.05832 0.49047
SX10 78 0.07533 0.40879
SX15 98 −0.05162 0.36561
SX20 118 0.02436 0.33095
Simulations produced datasets containing 4000 observations.
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics
showing the agreement between each diagnosis and Central adjudication di-
agnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for SX3-SX20 respectively.
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